Market Research Industry Reports

Recordati SpA (REC) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals in various therapeutic areas such as cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, over the counter (OTC) and non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, and others. Its also produces pharmaceutical chemicals, such as active pharmaceutical ingredients (APIs) and intermediates. Recordati conducts research and development of new specialties within the urogenital therapeutic area and for treatments of rare diseases. The company offers its products in Europe, USA, North Africa and Other international sales. Recordati is headquartered in Milano, Italy.

Recordati SpA (REC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati SpA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
Private Equity 23
CVC Fund to Acquire Majority Stake in Recordati for USD3504.6 Million 23
Partnerships 25
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Licensing Agreements 28
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 31
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 32
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Acquisition 39
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA - Key Competitors 46
Recordati SpA - Key Employees 47
Recordati SpA - Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 51
Financial Announcements 51
May 08, 2018: Recordati Announces Sales and Margin Growth in the First Quarter 2018 51
Mar 15, 2018: Recordati: Board Approves The 201 7 Accounts 52
Feb 08, 2018: Recordati: Preliminary 2017 Results Confirm Continued Growth of Sales and Profitability. Sales +11.6%, Operating Income +24.1%, Net Income +21.6% 55
Oct 26, 2017: Recordati: Very Good Results in the First Nine Months 2017. Continued Growth in Sales +11.8%, Operating Income +21.8%, Net Income +20.6%. Interim Dividend 0.42 (+20%) 56
Jul 27, 2017: Recordati: Very Good Results In The First Half 2017. Continued Growth In Sales +10.7%, Operating Income +19.4%, Net Income +19.8% 58
May 04, 2017: Recordati: Excellent Results in the First Quarter 2017. Continued Growth in Sales +13.1%, Operating Income +19.0%, Net Income +19.9% 60
Mar 01, 2017: Recordati: Board Approves The 2016 Accounts. Sales 1,153.9 Million (+10.1%), Operating Income 327.4 Million (+17.6%) And Net Income 237.4 Million (+19.4%). 2016 Dividend 0.70 (+16.7%) 61
Feb 09, 2017: Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List Of Tables

List of Tables
Recordati SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Recordati Acquires Rights to Cystagon from Mylan 13
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14
Recordati Acquires Rights for Seloken from Astrazeneca 15
Recordati Rare Diseases Acquires North American Rights to Cystadane 16
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For US$100 Million 17
Recordati Completes Acquisition Of Portfolio Of Products From Akvion For US$87 Million 19
Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21
Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22
CVC Fund to Acquire Majority Stake in Recordati for USD3504.6 Million 23
Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27
Recordati Enters into Licensing Agreement with MimeTech 28
Recordati Enters into Licensing Agreement with Meyer Hospital 29
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 31
Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 32
Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34
Plethora Enters into Licensing Agreement with Recordati for PSD502 36
Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38
Recordati Acquires Pro Farma for USD16.2 Million 39
Recordati Acquires Italchimici for up to USD145 Million 40
Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41
Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For US$122.5 Million 43
Recordati Completes Acquisition Of Farma-Projekt For US$21 Million 45
Recordati SpA, Key Competitors 46
Recordati SpA, Key Employees 47
Recordati SpA, Subsidiaries 48

List Of Figures

List of Figures
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Recordati SpA (REC) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals in various therapeutic areas such as cardiovascular,

USD 250View Report

Recordati S.p.A. - Mergers and Acquisitions (M&A), Partnerships and Alliances and Investment Report

Recordati S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Recordati S.p.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350View Report

Recordati SpA Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Recordati SpA Company Profile is a detailed strategic and analytical report on Recordati SpA. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Recordati SpA (REC) - Financial and Strategic SWOT Analysis Review

Recordati SpA (REC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :65
Country :Italy
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube